Abstract
IMPORTANCE Clinical diagnoses of psychiatric disorders are associated with cardiometabolic diseases (CMDs) such as type 2 diabetes and ischemic heart diseases. Studying how genetic liability for psychiatric disorders relate to CMD risk will offer novel insight into the relationship between psychiatric disorders and CMDs.
OBJECTIVE To evaluate the associations between psychiatric polygenic risk scores (PRSs) and clinically diagnosed CMDs while accounting for cross-disorder pleiotropy.
DESIGN, SETTING, AND PARTICIPANTS This study computed PRSs for attention deficit-hyperactivity disorder (ADHD), major depressive disorder (MDD), anxiety disorder, post-traumatic stress disorder (PTSD), bipolar disorder, and schizophrenia. The analysis was conducted in three population-based Northern European cohorts: the Swedish Twin Registry (STR, N=17,378 genotyped samples), the Estonian Biobank (EstBB, N=208,383), and the Norwegian Mother, Father and Child Cohort Study (MoBa, N=129,398). Associations between psychiatric PRSs and clinical diagnoses of 10 major CMDs (including metabolic diseases such as hyperlipidemia, obesity, and type 2 diabetes, and cardiovascular diseases such as hypertensive disease, arteriosclerosis, ischemic heart disease, heart failure, thromboembolic disease, cerebrovascular disease, and arrhythmias) were estimated using models that mutually adjusted for all psychiatric PRSs. Supplementary analyses were performed by additionally controlling for self-reported body mass index (BMI). A discordant twin-pair analysis was conducted in the STR (N=70,619) to assess the association between self-reported lifetime MDD and subsequent CMD risk while adjusting for familial factors shared between monozygotic and dizygotic co-twins.
MAIN OUTCOMES AND MEASURES Psychiatric PRSs were constructed based on both all available genetic risk variants and genome-wide significant risk variants from large-scale GWASs. Clinical diagnoses of psychiatric disorders and CMDs were ascertained through electronic health records (with primary care records used exclusively in the EstBB). Lifetime self-reported MDD in the STR was assessed via the Composite International Diagnostic Interview Short Form.
RESULTS PRSs for ADHD and MDD were associated with increased risk of all CMDs. The ADHD PRS showed stronger associations with metabolic disease, whereas the MDD PRS showed stronger associations with cardiovascular diseases. PRSs for anxiety disorder, PTSD, and bipolar disorder showed only limited associations with CMDs, while increased levels of schizophrenia PRSs were associated with decreased risk of CMDs. These associations remained after adjustment for BMI. Finally, twins endorsing lifetime MDD were found to have an increased risk of subsequent CMD diagnoses compared to their unexposed co-twins.
CONCLUSIONS AND RELEVANCE PRSs for ADHD and MDD showed robust associations with risk of CMDs and self-reported MDD was associated with subsequent CMD risk even after adjusting for familial factors shared between co-twins. These findings provide robust evidence for genetic overlap between ADHD and MDD with CMDs.
Competing Interest Statement
Dr Lewis sits on the SAB of Myriad Neuroscience and has received speaker/consultancy fees from SYNLAB and UCB. Dr Andreassen is a consultant to Cortechs.ai and Precision Health, and has received speaker's honoraria from Lundbeck, Janssen, Otsuka and Sunovion. Dr Sullivan has received consulting fees from and is a shareholder of Neumora Therapeutics. ZC received speaker fees from Takeda Pharmaceuticals, outside the submitted work.
Funding Statement
This work was supported by European Union's Horizon 2020 Research and Innovation Programme (CoMorMent project; grant no. 847776. REALMENT: grant no. 964874), European research council (grant no. 101042183) and NIH (LEGENNDS; R01NS131433, R01 MH123724).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Swedish Ethical Review Authority gave ethical approval for this work. The Regional Committees for Medical and Health Research Ethics gave ethical approval for this work. The Estonian Committee on Bioethics and Human Research (Estonian Ministry of Social Affairs) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data in this manuscript is available to authorized reserachers by formal application to the Swedish Twin Registry, the Estonian Biobank, and the MoBa study.
